Although TNF-α antagonists (infliximab, etanercept, adalimumab and certolizumab) have also been used as rescue therapy for ICI-induced colitis, arthritis and pneumonitis, controversial preclinical and clinical data about the effect of TNF-α antagonists on patients survival are currently available [40, 41]. This evidence concerns the gene TNF and pneumonitis.